Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 13/20 | 0.65 |
| ▸ | GSR | P00390 | 1/20 | 0.59 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.58 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.50 |
| ▸ | GNPAT | O15228 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL431293 | 1.00 | NOD1 (0.65) | NOD1GSRFOLH1SLC6A5PTGS1 | |
| SCHEMBL3250160 | 1.00 | NOD1 (0.65) | NOD1GSRFOLH1SLC6A5PTGS1 | |
| Lysine SCHEMBL28293082 | 0.98 | NOD1 (0.63) | NOD1GSRFOLH1SLC6A5PTGS1 | |
| SCHEMBL31124616 | 0.98 | NOD1 (0.63) | NOD1GSRFOLH1SLC6A5PTGS1 | |
| SCHEMBL28720707 | 0.95 | NOD1 (0.67) | NOD1GSRFOLH1SLC6A5PTGS1 | |
| SCHEMBL1986451 | 0.91 | FOLH1 (0.55) | NOD1GSRFOLH1SLC6A5GNPAT | |
| SCHEMBL8581110 | 0.91 | FOLH1 (0.55) | NOD1GSRFOLH1SLC6A5GNPAT | |
| SCHEMBL27397936 | 0.91 | NOD1 (0.60) | NOD1GSRFOLH1SLC6A5PTGS1 | |
| SCHEMBL9160515 | 0.89 | PTGS1 (0.61) | NOD1GSRFOLH1SLC6A5PTGS1 | |
| SCHEMBL1171265 | 0.89 | PTGS1 (0.61) | NOD1GSRFOLH1SLC6A5PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116046942-B | Composition and method for distinguishing difenoconazole sensitive type and drug-resistant type alternaria alternate strain and application | 福建省农业科学院植物保护研究所 | 2023-09-12 | — | — | CN | claimed |
| CN-116046942-A | Composition and method for distinguishing difenoconazole sensitive type and drug-resistant type alternaria alternate strain and application | 福建省农业科学院植物保护研究所 | 2023-05-02 | — | — | CN | claimed |
| US-20180275144-A1 | DIAGNOSTIC TOOLS FOR ALZHEIMER'S DISEASE | PHARNEXT (FR) | 2018-09-27 | — | — | US | claimed |
| US-20170067884-A1 | Method for the Early Detection of Autism Spectrum Disorder by use of Metabolic Biomarkers | GREENWOOD GENETIC CENTER | 2017-03-09 | — | — | US | claimed |
| WO-2016124574-A1 | DIAGNOSTIC TOOLS FOR ALZHEIMER'S DISEASE | PHARNEXT (FR) | 2016-08-11 | — | — | WO | claimed |
| CN-1842350-A | Crosslinked compositions comprising collagen and demineralized bone matrix | SDGI HOLDINGS INC (US) | 2006-10-04 | — | — | CN | claimed |
| CN-1126441-A | Amplification of vitamin B12 absorption System Using polymers | BIOTECH AUSTRALIA PTY LTD (AU) | 1996-07-10 | — | — | CN | claimed |
| WO-1992000383-A1 | ANTIBODIES SPECIFIC FOR THE TRANSGLUTAMINASE-INDUCED ISOPEPTIDE BOND | CIS BIO INTERNATIONAL (FR) | 1992-01-09 | — | — | WO | claimed |
| US-20260069656-A1 | Nutritive Polypeptides and Formulations Thereof, and Methods of Production and Use Thereof | AXCELLA HEALTH INC (US) | 2026-03-12 | — | — | US | disclosed |
| CN-113382712-B | Cosmetic composition of liquid crystalline lipid particles for personal care applications | 巴斯夫欧洲公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-118354792-A | Methods for treating progressive chronic interstitial lung disease | UCB生物制药有限责任公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-118317977-A | Method for treating scleroderma | UCB生物制药有限责任公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118175989-A | Formulations | UCB生物制药有限责任公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-118119377-A | Formulations | UCB生物制药有限责任公司 | 2024-05-31 | — | — | CN | disclosed |
| EP-0478366-A2 | Recombinant hybrid immunoglobulin molecules and method of use | THE GENERAL HOSPITAL CORPORATION (US) | 1992-04-01 | — | — | EP | disclosed |
| WO-1992000383-A1 | ANTIBODIES SPECIFIC FOR THE TRANSGLUTAMINASE-INDUCED ISOPEPTIDE BOND | CIS BIO INTERNATIONAL (FR) | 1992-01-09 | — | — | WO | disclosed |
| EP-0443724-A1 | Viral-safe purified human thrombin | BAXTER INTERNATIONAL INC. (US) | 1991-08-28 | — | — | EP | disclosed |
| WO-1990002338-A1 | RECOMBINANT HYBRID IMMUNOGLOBULIN MOLECULES AND METHOD OF USE | THE GENERAL HOSPITAL CORPORATION (US) | 1990-03-08 | — | — | WO | disclosed |
| EP-0355068-A2 | Recombinant hybrid immunoglobulin molecules and their use | THE GENERAL HOSPITAL CORPORATION (US) | 1990-02-21 | — | — | EP | disclosed |
| EP-0271227-A2 | Recombinant hybrid immunoglobulin molecules and their use | THE GENERAL HOSPITAL CORPORATION (US) | 1988-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069656-A1 | Nutritive Polypeptides and Formulations Thereof, and Methods of Production and Use Thereof | TTPA, VIP, GC | NOD1 2378/4885GSR 2178/4885FOLH1 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.